MC2 Therapeutics has enrolled the first patients in a Phase II proof of concept (PoC) trial assessing the new drug candidate, MC2-25 VLS, to treat urea-associated skin diseases, including Vulvar ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--City Therapeutics, Inc. announced its launch today with a vision to lead the future of RNA interference (RNAi)-based medicine. City Therapeutics™ aims to ...

Two pioneering digital therapeutics (DTx) for addiction are available once again after their original developer Pear Therapeutics was dissolved last year. The AI effect in pharma commercial ...

The Fna C2 subtype also appeared more often in stool samples collected ... who is a cancer microbiome researcher at the center. "It suggests therapeutics and screening that target this subgroup within ...

--(BUSINESS WIRE)--PursueCare, a leader in virtual addiction treatment, today announced the rollout of RESET ® and RESET-O ®, the only FDA-authorized prescription digital therapeutics ...

SAN DIEGO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic delivery, today is sharing progress on its development of the ...

Therapeutics are treatments used to alleviate or prevent a particular disease. Examples of therapeutics include drug therapy, medical devices, nutrition therapy and stem-cell therapies ...

The development of the anti-migraine therapeutics, triptans-5-HT 1B/1D ... the trigeminal nucleus caudalis and the C1 and C2 regions of the spinal cord, collectively known as the trigeminocervical ...

Five years and five more approved drugs later, RNAi therapeutics are a proven class of medicines, and the potential for further innovation remains. “This is changing the practice of medicine ...

1 Day NTLA 4.60% DJIA 0.69% S&P Mid Cap 400 0.86% Health Care/Life Sciences -0.64% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent ...

Viking Therapeutics (NASDAQ:VKTX) added ~18% on Thursday to reach a five-month high as Wall Street focused on updates on its obesity candidate VK2735, even as the company posted better-than ...

(TGTX) on Monday reported third-quarter earnings of $3.9 million. On a per-share basis, the Morrisville, New York-based company said it had profit of 2 cents.